Center for Women's Health Research and Innovation (CWHRI).
Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh.
Curr Opin Rheumatol. 2021 Nov 1;33(6):570-578. doi: 10.1097/BOR.0000000000000839.
People with childbearing capacity who are diagnosed with systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS) have specific and important reproductive health considerations.
Recommendations from the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) provide rheumatologists and other clinicians with guidance for reproductive health management of patients with rheumatic diseases. Patient-centered reproductive health counseling can help clinicians to operationalize the EULAR and ACR guidelines and enhance patient care.
Disease activity monitoring, risk factor stratification, and prescription of pregnancy-compatible medications during pregnancy help to anticipate complications and enhance pregnancy outcomes in SLE and SS. Assisted reproductive technologies are also safe among people with well-controlled disease. Safe and effective contraceptive methods are available for patients with SLE and SS, and pregnancy termination appears to be safe among these patients.
诊断为系统性红斑狼疮（SLE）和干燥综合征（SS）的具有生育能力的人群具有特殊且重要的生殖健康方面的考虑。
欧洲抗风湿病联盟（EULAR）和美国风湿病学会（ACR）的建议为风湿病学家和其他临床医生提供了对患有风湿性疾病患者的生殖健康管理的指导。以患者为中心的生殖健康咨询可以帮助临床医生实施 EULAR 和 ACR 指南并改善患者护理。
疾病活动监测、危险因素分层和在怀孕期间开具适合妊娠的药物有助于预测 SLE 和 SS 中的并发症并改善妊娠结局。辅助生殖技术在疾病控制良好的人群中也是安全的。SLE 和 SS 患者可使用安全有效的避孕方法，且这些患者中终止妊娠似乎也是安全的。
